Protein misfolding and disease; protein refolding and therapy.
about
Leukocyte cell-derived chemotaxin 2 is a zinc-binding proteinIdentification of human plasma proteins as major clients for the extracellular chaperone clusterinPrion hypothesis: the end of the controversy?Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseasesPharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptorsMyofibrillar myopathy caused by a mutation in the motor domain of mouse MyHC IIbProcessing of surfactant protein C requires a type II transmembrane topology directed by juxtamembrane positively charged residuesSwitch region for pathogenic structural change in conformational disease and its predictionFast and Accurate Accessible Surface Area Prediction Without a Sequence Profile.Modeling the resolution and sensitivity of FAIMS analyses.Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator.The mechanism of enhanced insulin amyloid fibril formation by NaCl is better explained by a conformational change modelPharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosaQuality control of protein folding in extracellular space.Feasibility of β-sheet breaker peptide-H102 treatment for Alzheimer's disease based on β-amyloid hypothesis.Protein-misfolding diseases and chaperone-based therapeutic approaches.Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease.Control of peptide conformation by the Thorpe-Ingold effect (C alpha-tetrasubstitution).Can misfolded proteins be beneficial? The HAMLET case.A network of protein interactions determines polyglutamine toxicity.The structural biochemistry of the superoxide dismutases.Site-directed mutagenesis reveals regions implicated in the stability and fiber formation of human λ3r light chainsCu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro.Misfolded proteins in Alzheimer's disease and type II diabetes.Active protein aggregates produced in Escherichia coliFuture directions in the treatment of Alzheimer's disease.Developing master keys to brain pathology, cancer and aging from the structural biology of proteins controlling reactive oxygen species and DNA repair.Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.Stabilization of partially folded states in protein folding/misfolding transitions by hydrostatic pressure.Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding.Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases.Protein Mechanics: A New Frontier in Biomechanics.Denaturation and solvent effect on the conformation and fibril formation of TGFBIp.Cross currents in protein misfolding disorders: interactions and therapy.Alzheimer's disease: from molecular pathogenesis to innovative therapies.Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.E3 ubiquitin ligases in protein quality control mechanism.Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets.Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey.
P2860
Q24311787-1AD6434E-9F14-4F0F-A542-D95BEF893836Q24336992-7F7D723B-959C-4009-9373-8C0651FF4A12Q24599702-981A806C-F11F-485B-A5AD-6DAC82322813Q24633202-D2945EF7-7086-463B-8612-0D7339F16838Q26992276-0F224F73-291E-4B57-A230-E67AE7BC5ECFQ28513616-F7489228-8312-47DA-A659-3B1EB0D2CC59Q28583232-93780D2F-39FB-482E-971E-2FF8B174F087Q30384993-AF9AF18A-9616-4A8D-9ED9-6469C5D7B8F1Q30394577-8D5E81DB-3CED-4278-A8B3-656A55226D8FQ33432284-9E84D7F5-EA8B-4814-A6FE-8070F58A7C9BQ33973031-E35B0B73-FB61-4EC4-8CA7-11EBC336888CQ34087988-818E1215-613A-43D2-A746-F8AFB4178869Q34338708-F1E27ECC-53CB-48A4-96A0-D919ADC9F4EEQ34360699-DFF1262E-A465-4D65-9B0B-3DAD21219A40Q34457296-0358DFDC-3508-4241-AC62-7AE82AA72737Q34524526-FEEDDC29-3CEA-4E5C-AEC9-DAEF8ADF307BQ34756441-C798889F-BCD2-429F-B5EB-1E9DF232F45BQ34810582-90CCB250-BC1E-45EC-BFC0-B6ECEA5BC218Q34873055-D92DAFA6-41E0-4568-9368-EF9B12579430Q34984299-FE0757AA-697D-43E5-98F8-5E0933FDF1D1Q34993111-0988FCE3-649D-4C15-8C8C-888DB7FE530DQ35048946-C04D3F1D-6AE9-4AC8-979C-7B851DD35257Q35162930-10D3C02E-D9AB-4788-96D7-7228F09BC329Q35535599-8E1C093A-030F-495B-A20B-CFD65F5265ECQ35600257-9A107939-0758-4FEB-8E0F-46A057D17075Q35753450-DBF06173-D56C-4533-92E3-77120471CC61Q35865533-D6BD9690-CE87-4867-8721-9912A76C0D43Q35915771-0D0D2143-5E40-487E-B466-8B88E86CE723Q36219394-35B915BD-A0B1-4A23-A3A0-55D2D88206EEQ37108161-C3D9343A-DBFB-40B5-960E-7B5570D9CFA5Q37351126-61B7074C-4C4B-4841-A9A4-7E9BEEEC9AA7Q37369854-250B37EE-BB73-490A-AC02-066362F1C27DQ37374292-C89EEE97-A266-432A-8319-90B74E7AEB58Q37465828-CF289059-C179-418B-8B72-EC277DD268B8Q37585420-BBB93FD7-26A7-41B2-AA1C-2BE4820E0074Q37610251-BF84B48B-D9F7-4F82-8024-DC039DDD601BQ37875484-4698C788-1878-4B19-A9C0-4E6A484B27C1Q38011658-14FA492B-ADAA-45E4-8DDE-6FE7A8C36760Q38048236-D13BADE3-DD38-4947-B31D-4796DC67E585Q38075593-04AF75C3-FE3A-461B-9ED2-E16C8C73F4BA
P2860
Protein misfolding and disease; protein refolding and therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Protein misfolding and disease; protein refolding and therapy.
@ast
Protein misfolding and disease; protein refolding and therapy.
@en
Protein misfolding and disease; protein refolding and therapy.
@nl
type
label
Protein misfolding and disease; protein refolding and therapy.
@ast
Protein misfolding and disease; protein refolding and therapy.
@en
Protein misfolding and disease; protein refolding and therapy.
@nl
prefLabel
Protein misfolding and disease; protein refolding and therapy.
@ast
Protein misfolding and disease; protein refolding and therapy.
@en
Protein misfolding and disease; protein refolding and therapy.
@nl
P2860
P1433
P1476
Protein misfolding and disease; protein refolding and therapy.
@en
P2093
P2860
P304
P356
10.1016/S0014-5793(01)02486-3
P407
P577
2001-06-01T00:00:00Z